America’s Food and Drug Administration approved a medication produced by Eli Lilly, a pharmaceutical firm, for weight-loss use. The injectable, called Zepbound, is part of a new generation of obesity drugs, and has the same active ingredient as Mounjaro, which is already approved to treat diabetes. It will compete against Novo Nordisk’s Wegovy, the weight-loss version of Ozempic.
America’s Food and Drug Administration approved a medication...
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$32.84 |
Change
0.410(1.26%) |
Mkt cap ! $20.85B | |||
| Open | High | Low | Value | Volume |
| $32.65 | $32.84 | $32.61 | $14.53M | 443.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 1510 | $32.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $32.85 | 1178 | 11 |
View Market Depth
| Last trade - 12.00pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$32.86 |
Change
0.410 ( 1.37 %) |
||||
| Open | High | Low | Volume | ||
| $32.62 | $32.89 | $32.62 | 44229 | ||
| Last updated 12.19pm 21/05/2024 ? | |||||
| RMD (ASX) Chart |